Skip to main content

September 2015

Novartis announced today that Swissmedic has approved Entresto(TM) (sacubitril/valsartan), previously known as LCZ696, to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Entresto will be available on prescription for adult patients whose condition is classified NYHA class II-IV and with an ejection fraction of 40% or less. It is administered in combination with other heart failure therapies as appropriate, in place of an ACE inhibitor or angiotensin receptor blocker.

New research suggests that bacteria residing in our skin may help fight infections caused by chancroid, a sexually transmitted disease (STD). The findings suggest that skin microbiome can influence the outcomes of a bacterial infection. The study was published in the journal mBio.

Vacancy for B.Pharm/D.Pharm as Research Assistant in AIIMS, Rishikesh

A Research Assistant is required for the intramural project entitled "Knowledge Attitude and Disposal practices among drug stores in North India" at Department of Pharmacology, AIIMS, Rishikesh

Post: Research Assistant

Work as Global Trial Leader in Novartis

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Post: Global Trial Leader